This group of patients should be identified as soon as possible so they could early receive aggressive or new therapeuties such as the antibody- drug conjugate brentuximab vedotin and anti PD-L1, which has already shown efficacy in adults and in few cases of pediatric refractory HL [22, 23]. Here, CD274 is linked to Hodgkins lymphoma.